NCT ID,Brief Title,Official Title,Study Type,Recruitment Status,Current Phase,Phase Details,Start Date,Completion Date,Primary Completion Date,Conditions Treated,Interventions,Intervention Types,Intervention Names,Lead Sponsor,All Sponsors,Sponsor Types,Study Locations,Countries,Cities,Enrollment,Study Population,Is Interventional,Has Drug Intervention,Has Device Intervention,Has Procedure Intervention,Has Behavioral Intervention,Has Biological Intervention,Has Radiation Intervention,Is Phase 0,Is Phase 1,Is Phase 2,Is Phase 3,Is Phase 4,Is Recruiting,Is Completed,Is Terminated,Is Suspended,Is Not Yet Recruiting,Is Active Not Recruiting
NCT02587312,Evaluation of Very Low Nicotine Content Cigarettes in Adolescent Smokers,Evaluation of Very Low Nicotine Content Cigarettes in Adolescent Smokers,INTERVENTIONAL,COMPLETED,NA,NA,2016-10-13T00:00:00,2019-08-31T00:00:00,2019-08-28T00:00:00,Nicotine Dependence,Very low nicotine content cigarettes (OTHER); Standard nicotine content cigarettes (OTHER),OTHER; OTHER,Very low nicotine content cigarettes; Standard nicotine content cigarettes,Brown University,Brown University,OTHER,,,,,,True,False,False,False,False,False,False,False,False,False,False,False,False,True,False,False,False,False
NCT00088881,"Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma",A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients With Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma,INTERVENTIONAL,TERMINATED,PHASE2,Phase 2 (Efficacy),2004-12-01T00:00:00,2011-03-01T00:00:00,2011-03-01T00:00:00,Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Testicular Lymphoma; Waldenstr√∂m Macroglobulinemia,rituximab (BIOLOGICAL); prednisone (DRUG); cyclophosphamide (DRUG); doxorubicin (DRUG); vincristine (DRUG); indium In 111 ibritumomab tiuxetan (RADIATION); radiation therapy (RADIATION); positron emission tomography (PROCEDURE),BIOLOGICAL; DRUG; DRUG; DRUG; DRUG; RADIATION; RADIATION; PROCEDURE,rituximab; prednisone; cyclophosphamide; doxorubicin; vincristine; indium In 111 ibritumomab tiuxetan; radiation therapy; positron emission tomography,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,,,,,,True,True,False,True,False,True,True,False,False,True,False,False,False,False,True,False,False,False
NCT06956781,Multiphase Optimization Strategy (MOST) for Treating Pediatric Post-traumatic Stress Disorder (PTSD),Optimizing Behavioral Health Services Following Pediatric Trauma Exposure,INTERVENTIONAL,NOT_YET_RECRUITING,NA,NA,2025-09-01T00:00:00,2028-08-01T00:00:00,2028-08-01T00:00:00,PTSD; Trauma; Pediatric ALL,Emotion Regulation (BEHAVIORAL); Exposure (BEHAVIORAL); Cognitive Processing (BEHAVIORAL); Bi-lateral Stimulation (BEHAVIORAL); Psychological Placebo (BEHAVIORAL),BEHAVIORAL; BEHAVIORAL; BEHAVIORAL; BEHAVIORAL; BEHAVIORAL,Emotion Regulation; Exposure; Cognitive Processing; Bi-lateral Stimulation; Psychological Placebo,University of Rochester,University of Rochester,OTHER,,,,,,True,False,False,False,True,False,False,False,False,False,False,False,False,False,False,False,True,False
NCT01854112,Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma,,INTERVENTIONAL,UNKNOWN,,Not specified,2012-11-01T00:00:00,,2017-12-01T00:00:00,T-cell Lymphoma,,,,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,OTHER,,,,,,True,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False,False
NCT00075881,Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma,"Phase II Study of PS-341 for Patients With High-Risk, Newly Diagnosed Multiple Myeloma",INTERVENTIONAL,COMPLETED,PHASE2,Phase 2 (Efficacy),2004-01-01T00:00:00,2012-10-01T00:00:00,2012-10-01T00:00:00,Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma,bortezomib (DRUG); laboratory biomarker analysis (OTHER),DRUG; OTHER,bortezomib; laboratory biomarker analysis,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,,,,,,True,True,False,False,False,False,False,False,False,True,False,False,False,True,False,False,False,False
